FIELD: medical biotechnology.
SUBSTANCE: disclosed is the use of a muropeptide postbiotic, which is an absolutely specific agonist to NOD2 receptors, in which the ratio of the relative expression of the pro-inflammatory cytokine IL-1β and anti-inflammatory cytokines does not exceed value of 1.5, for complex correction of secondary immune deficiency syndrome and associated dysbiosis in oncological and comorbid patients with chronic non-infectious diseases.
EFFECT: invention enables complex correction of secondary immune deficiency syndrome and associated dysbiosis in oncological and comorbid patients with chronic non-infectious diseases.
1 cl, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR FUNCTIONAL ENTERAL DIETARY NUTRITION CONTAINING MUROPEPTIDE POSTBIOTIC, WHICH IS ABSOLUTELY SPECIFIC AGONIST TO NOD2 RECEPTORS | 2024 |
|
RU2831610C1 |
| METHOD OF TREATING CHRONIC RHINOSINUSITIS | 2011 |
|
RU2469737C1 |
| METHOD FOR PREDICTION OF SEPSIS FOLLOWING CARDIOSURGICAL OPERATIONS PERFORMED IN CONDITIONS OF ARTIFICIAL BLOOD CIRCULATION | 2019 |
|
RU2713930C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN CHRONIC PURULENT RHINOSINUSITIS | 2008 |
|
RU2379050C2 |
| METHOD OF IMMUNOTHERAPY OF PURULENT RHINOSINUSITIS | 2010 |
|
RU2457789C2 |
| METHOD OF IMMUNOTHERAPY OF PURULENT RHINOSINUSITIS | 2009 |
|
RU2408385C1 |
| SOLUTIONS AND METHODS FOR INHIBITING PAIN, CARTILAGE INFLAMMATION AND DESTRUCTION | 2000 |
|
RU2271825C2 |
| ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS BASED ON BACTERIAL STRAIN | 2015 |
|
RU2616899C1 |
| METHOD FOR PROGNOSIS OF TREATMENT EFFECTIVENESS WITH RECOMBINANT CYTOKINE REGULATING INFLAMMATION | 2004 |
|
RU2271827C1 |
| COMPOSITION FOR MODULATION OF CELL ADHESION MOLECULE EXPRESSION | 2007 |
|
RU2503463C2 |
